Sugi Predict

Sugi Predict / Targets / BAZ2B

BAZ2B

Bromodomain adjacent to zinc finger domain protein 2B · Q9UIF8 · BAZ2B on Sugi Atlas →

20,875 patent compounds predicted against BAZ2B, 12,649 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL764099 SCHEMBL764099 0.73 13/20
SCHEMBL409534 SCHEMBL409534 0.71 13/20
SCHEMBL620034 SCHEMBL620034 0.86 12/20
SCHEMBL408122 SCHEMBL408122 0.59 12/20
SCHEMBL61377 SCHEMBL61377 0.53 12/20
SCHEMBL940082 SCHEMBL940082 0.53 12/20
SCHEMBL408088 SCHEMBL408088 0.52 12/20
SCHEMBL407766 SCHEMBL407766 0.53 11/20
SCHEMBL541660 SCHEMBL541660 0.57 10/20
SCHEMBL1004951 SCHEMBL1004951 0.55 7/20
SCHEMBL61901 SCHEMBL61901 0.47 7/20
SCHEMBL941608 SCHEMBL941608 0.46 7/20
SCHEMBL407460 SCHEMBL407460 0.74 6/20
SCHEMBL409485 SCHEMBL409485 0.52 6/20
SCHEMBL1120415 SCHEMBL1120415 0.65 5/20
SCHEMBL168946 SCHEMBL168946 0.59 5/20
SCHEMBL168914 SCHEMBL168914 0.56 5/20
SCHEMBL1120454 SCHEMBL1120454 0.54 5/20
SCHEMBL168662 SCHEMBL168662 0.54 5/20
SCHEMBL1120686 SCHEMBL1120686 0.53 5/20

Clinical trials — most relevant to BAZ2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Better Delineation of BCL11B Related Phenotype and Epigenetic Signature. nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BAZ2B binder may also engage these)

ProteinNameSimilarity
Q9DE13 — 0.998 Q9DE13 →
Q86UP3 — 0.995 Q86UP3 →
Q8IZQ8 — 0.994 Q8IZQ8 →
A2AUY4 — 0.994 A2AUY4 →
Q03112 — 0.993 Q03112 →
Q5ZM88 — 0.993 Q5ZM88 →
O42477 — 0.993 O42477 →
Q4G0F8 — 0.993 Q4G0F8 →
Q5U4Q0 — 0.992 Q5U4Q0 →
E1BE02 — 0.992 E1BE02 →
Q86SQ0 — 0.992 Q86SQ0 →
Q8BZ32 — 0.991 Q8BZ32 →
Q69ZK6 — 0.991 Q69ZK6 →
Q07E15 — 0.991 Q07E15 →
Q5RIX9 — 0.991 Q5RIX9 →
Q86V15 — 0.991 Q86V15 →
TFDP2 Transcription factor Dp-2 0.991 landscape →
Q8CCJ9 — 0.990 Q8CCJ9 →
O13089 — 0.990 O13089 →
P40645 — 0.990 P40645 →
Q9YGY4 — 0.990 Q9YGY4 →
O60293 — 0.990 O60293 →
Q0V9U1 — 0.990 Q0V9U1 →
Q6ZSZ6 — 0.990 Q6ZSZ6 →
Q3UHI0 — 0.990 Q3UHI0 →
Q9ULJ3 — 0.990 Q9ULJ3 →
Q8R5I7 — 0.990 Q8R5I7 →
Q09YI1 — 0.990 Q09YI1 →
Q5ZIE8 — 0.989 Q5ZIE8 →
Q9JJN2 — 0.989 Q9JJN2 →